General
Preferred name
OROTIC ACID
Synonyms
Vitamin B13 ()
6-Carboxyuracil ()
2,4-dioxo-1H-pyrimidine-6-carboxylic acid hydrate ()
Orotic Acid Monohydrate ()
2,6-Dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid hydrate ()
Orotic acid (6-Carboxyuracil), 6-Carboxyuracil, Orodin, Oropur, Orotonin, Orotonsan ()
Orotate ()
Orotic acid (hydrate) ()
Orotic acid (6-Carboxyuracil) ()
Zinc orotate ()
Acido orotico ()
Whey factor ()
Animal galactose factor ()
NSC-9791 ()
Orotyl ()
Acide orotique ()
Oropur ()
P&D ID
PD001471
CAS
68460-00-4
60388-02-5
68399-76-8
65-86-1
73-97-2
50887-69-9
Tags
available
drug candidate
drug
Drug indication
Discovery agent
Drug Status
approved
investigational
experimental
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Orotic acid has been assigned an INN in its own right and is also a component of the INN-assigned compound orazamide.
(GtoPdb)
DESCRIPTION
Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[1][2][3].
PRICE
29
DESCRIPTION
Orotic acid hydrate is an endogenous metabolite.
PRICE
29
DESCRIPTION
Orotic acid is a heterocyclic compound and an acid. It is manufactured in the body via a mitochondrial enzyme, dihydroorotate dehydrogenase, or a cytoplasmic enzyme of pyrimidine synthesis pathway.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Orotic acid is a drug used to manage uncomplicated liver dysfunction in combination with xanthine. It also inhibits T. gondii OPRTase with Ki = 3.9 µM.
(Enamine Bioactive Compounds)
DESCRIPTION
Orotic acid (Vitamin B13) is an intermediate product in pyrimidine metabolism.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Orotic acid monohydrate is an intermediate product in pyrimidine metabolism.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
22
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
79
Molecular Weight
156.02
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
1
Ring Count
1
Aromatic Ring Count
1
cLogP
-1.24
TPSA
103.02
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
DHOase
Endogenous Metabolite
Nucleoside antimetabolite/analog
Apoptosis
DHODH
MOA
Dehydrogenase
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Source data
